Comparison of finasteride (proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition

Rhodes, Linda; Primka, R. L.; Berman, Charles L.; Vergult, Gerard; Gabriel, Mordecai; Pierre‐Malice, Marie; Gibelin, B.

doi:10.1002/pros.2990220107

Cited by 119 publications

(57 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, serum dihydrotestosterone did not decrease, indicating that the inhibition of 5-␣ reductase is not an important part of the mechanism (table 4). [15][16][17] Since we noted no effect of saw palmetto herbal blend on prostate inflammatory tissues, we did not confirm the antiinflammatory hypothesis of Helpap et al 18 An unexplained finding in our series is the lack of a change in serum PSA despite marked epithelial contraction. This apparent paradox may involve some novel mechanism of action that was not detected in our studies of apoptosis, cell proliferation, growth factors, angiogenesis and androgen receptor expression.…”

Section: Discussioncontrasting

confidence: 81%

Effects of a Saw Palmetto Herbal Blend in Men With Symptomatic Benign Prostatic Hyperplasia

Marks¹,

Partin²,

Epstein³

et al. 2000

The Journal of Urology

View full text Add to dashboard Cite

Purpose: We tested the effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia (BPH) via a randomized, placebo controlled trial.Materials and Methods: We randomized 44 men 45 to 80 years old with symptomatic BPH into a trial of a saw palmetto herbal blend versus placebo. End points included routine clinical measures (symptom score, uroflowmetry and post-void residual urine volume), blood chemistry studies (prostate specific antigen, sex hormones and multiphasic analysis), prostate volumetrics by magnetic resonance imaging, and prostate biopsy for zonal tissue morphometry and semiquantitative histology studies.Results: Saw palmetto herbal blend and placebo groups had improved clinical parameters with a slight advantage in the saw palmetto group (not statistically significant). Neither prostate specific antigen nor prostate volume changed from baseline. Prostate epithelial contraction was noted, especially in the transition zone, where percent epithelium decreased from 17.8% at baseline to 10.7% after 6 months of saw palmetto herbal blend (p Ͻ0.01). Histological studies showed that the percent of atrophic glands increased from 25.2% to 40.9% after treatment with saw palmetto herbal blend (p Ͻ0.01). The mechanism of action appeared to be nonhormonal but it was not identified by tissue studies of apoptosis, cellular proliferation, angiogenesis, growth factors or androgen receptor expression. We noted no adverse effects of saw palmetto herbal blend. When the study was no longer blinded, 41 men elected to continue therapy in an open label extension.Conclusions: Saw palmetto herbal blend appears to be a safe, highly desirable option for men with moderately symptomatic BPH. The secondary outcome measures of clinical effect in our study were only slightly better for saw palmetto herbal blend than placebo (not statistically significant). However, saw palmetto herbal blend therapy was associated with epithelial contraction, especially in the transition zone (p Ͻ0.01), indicating a possible mechanism of action underlying the clinical significance detected in other studies.

show abstract

Section: Discussioncontrasting

confidence: 81%

Effects of a Saw Palmetto Herbal Blend in Men With Symptomatic Benign Prostatic Hyperplasia

Marks¹,

Partin²,

Epstein³

et al. 2000

The Journal of Urology

View full text Add to dashboard Cite

show abstract

“…to assess this variable because no reduction could be expected with b-sitosterol [24]. This was also confirmed The present multicentre trial used the IPSS as the primary outcome variable, according to international by the results of Berges et al…”

Section: Discussionsupporting

confidence: 80%

“…Keywords b-sitosterol therapy, symptom score, benign (Q max ) and post-void residual urinary volume (PVR) were recorded. The drug used in the trial consisted of prostatic hyperplasia a chemically defined extract of phytosterols, derived BPH (1991 and1993) [13,14] and reports the results …”

mentioning

confidence: 99%

A multicentric, placebo‐controlled, double‐blind clinical trial of β‐sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia

Klippel

Hiltl

Schipp

1997

British Journal of Urology

164

View full text Add to dashboard Cite

Objective To report the results of a double-blind, placebofor example from species of Pinus, Picea or Hypoxis, with b-sitosterol as the main component. controlled trial to evaluate AzuprostatA , a b-sitosterol, in patients with symptoms of outlet obstruction causedResults There were significant (P<0.01) improvements over placebo in those treated with b-sitosterol; the by benign prostatic hyperplasia (BPH). Patients and methods A randomized, double-blind mean diÂerence in the IPSS between placebo and b-sitosterol, adjusted for the initial values, was 5.4 and placebo-controlled clinical trial was conducted to assess the eÃcacy and safety of 130 mg free and in the quality-of-life index was 0.9. There were also significant improvements in the secondary outb-sitosterol (phytosterol) daily, using the international prostate symptom score (IPSS) as the primary outcome come variables, with an increase in Q max (4.5 mL/s) and decrease in PVR (33.5 mL) in favour of b-sitosterol variable. In total, 177 patients with BPH were recruited for 6 months of treatment in 13 study when adjusted for the changes after placebo. Conclusion These results show that b-sitosterol is an centres. In addition to the relative diÂerence in the IPSS, changes in quality of life, peak urinary flow rate eÂective option in the treatment of BPH. Keywords b-sitosterol therapy, symptom score, benign (Q max ) and post-void residual urinary volume (PVR) were recorded. The drug used in the trial consisted of prostatic hyperplasia a chemically defined extract of phytosterols, derived BPH (1991 and1993) [13,14] and reports the results

show abstract

“…However, little is known about how pumpkin seed oil (PSO) alone or in combination infl uences prostatic growth. Experimental prostate growth procedures using a variety of agents, including dihyroxytestosterone or testosterone, estrogen, prazosin (an ␣ 1 -adrenergic antagonist), and ␣ 2 -agonists or ␣ 2 -antagonists, or their combinations, were reported to be able to increase prostate weight [14] and were widely used in animal models for studying their impact on chronic urinary tract obstruction [15] or for studying the effect of various agents or plant extracts [16,17] .…”

mentioning

confidence: 99%

Pumpkin Seed Oil and Phytosterol-F Can Block Testosterone/Prazosin-Induced Prostate Growth in Rats

Tsai

Tong²,

Cheng

et al. 2006

Urol Int

View full text Add to dashboard Cite

Introduction: This study was undertaken to investigate the effects of pumpkin seed oil alone or combined with Phytosterol-F on testosterone/prazosin-induced (T-P) prostate growth in rats. Materials and Methods: Forty adult Wistar rats were divided into five groups, including: one control group, rats treated with vehicle only, one group treated with T-P, and two groups of T-P-treated rats, one receiving orally pumpkin seed oil alone and one group receiving orally pumpkin seed oil combined with Phytosterol-F. Two weeks later, the prostatic weight-to-body weight ratio was determined after sacrifice. The total protein concentration was measured by using a protein assay. Some ventral prostatic tissues were histologically examined after hematoxylin-eosin staining. Results: Histological sections of the ventral prostate showed that the architecture of the prostate glands became hyperplastic in the T-P rats, but not in the control or vehicle-treated animals. As compared with the control or vehicle group, T-P rats had a significantly higher prostatic weight-to-body weight ratio for the ventral prostate (p = 0.05 and p = 0.007, respectively), but not for the dorsolateral prostate (p = 0.53 and p = 0.73, respectively). The T-P rats had significantly higher protein levels within both lobes (ventral lobe, p = 0.02 and p < 0.0001, respectively; dorsolateral lobe, p = 0.06 and p = 0.005, respectively). As compared with the T-P-alone rats, the TP rats treated with pumpkin seed oil alone or pumpkin seed oil combined with Phytosterol-F had a significantly lower weight ratio for the ventral prostate (p = 0.01 and p = 0.004, respectively) and significantly lower protein levels within both lobes (p = 0.03 and p = 0.003, respectively; p = 0.007 and p = 0.002, respectively). In addition, Phytosterol-F had some additive effect on the total protein synthesis within the ventral prostate (p = 0.02). Conclusion: Pumpkin seed oil alone or combined with Phytosterol-F can block the T-P-induced increases in prostatic weight-to-body weight ratio and protein synthesis.

show abstract

Comparison of finasteride (proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition

Cited by 119 publications

References 13 publications

Effects of a Saw Palmetto Herbal Blend in Men With Symptomatic Benign Prostatic Hyperplasia

Effects of a Saw Palmetto Herbal Blend in Men With Symptomatic Benign Prostatic Hyperplasia

A multicentric, placebo‐controlled, double‐blind clinical trial of β‐sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia

Pumpkin Seed Oil and Phytosterol-F Can Block Testosterone/Prazosin-Induced Prostate Growth in Rats

Contact Info

Product

Resources

About

Comparison of finasteride (proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition

Cited by 119 publications

References 13 publications

Effects of a Saw Palmetto Herbal Blend in Men With Symptomatic Benign Prostatic Hyperplasia

Effects of a Saw Palmetto Herbal Blend in Men With Symptomatic Benign Prostatic Hyperplasia

A multicentric, placebo‐controlled, double‐blind clinical trial of &beta;‐sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia

Pumpkin Seed Oil and Phytosterol-F Can Block Testosterone/Prazosin-Induced Prostate Growth in Rats

Contact Info

Product

Resources

About

A multicentric, placebo‐controlled, double‐blind clinical trial of β‐sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia